Signaling of TGFb family members such as activin is tightly regulated by soluble binding proteins. Follistatin binds to activin A with high anity, and prevents activin binding to its own receptors, thereby blocking its signaling. We previously identi®ed FLRG gene from a B-cell leukemia carrying a t(11;19)(q13;p13) translocation. We and others have already shown that FLRG, which is highly homologous to follistatin, may be involved in the regulation of the activin function through its binding to activin. In this study, we found that, like follistatin, FLRG protein inhibited activin A signaling as demonstrated by the use of a transcriptional reporter assay, and blocked the activin A-induced growth inhibition of HepG2 cells. We have recently shown that the TGFb-induced expression of FLRG occurs at a transcriptional level through the action of Smad proteins. Here we show that activin A increases FLRG and follistatin at both the mRNA and protein levels. We found that Smad proteins are involved in the activin Ainduced transcription activation of FLRG and follistatin. Finally we demonstrate that FLRG protein regulates its own activin-induced expression. In conclusion, activin A induces FLRG and follistatin expression. This observation, in conjunction with the antagonistic eect of FLRG and follistatin on activin signaling, indicates that these two proteins participate in a negative feedback loop which regulates the activin function.
Introduction
We previously identi®ed a human gene, FLRG (Follistatin-related gene), from a B-cell chronic lymphocytic leukemia carrying a t(11;19)(q13;p13) translocation (Hayette et al., 1998) . FLRG is a secreted glycoprotein which is highly homologous to follistatin, a protein known to bind to activin, a member of the transforming growth factor b (TGFb) superfamily (Nakamura et al., 1990) . Activin and follistatin proteins were originally isolated from ovarian¯uid as a result of their ability to stimulate and inhibit, respectively, the secretion of follicle-stimulating hormone from the pituitary gland (Phillips and de Kretser, 1998) . Further studies have revealed that activin, a secreted protein produced by a variety of tissues, has important endocrine and paracrine roles. Activin has been shown to control fundamental processes such as cell proliferation and dierentiation, development and reproduction (DePaolo, 1997; Phillips and de Kretser, 1998; Ying et al., 1997) . Several reports have shown that activin, which is produced by bone marrow stromal cells (Yamashita et al., 1992) such as FLRG (Hayette et al., 1998) , is also involved in hematopoietic dierentiation, particularly in the erythroid lineage (Yu and Dolter, 1997) . We have previously shown that the expression of both FLRG and activin A is up-regulated during hematopoietic dierentiation, and in TGFbtreated human bone marrow stromal cells (MaguerSatta et al., 2001) . Several studies have revealed that the biological eects of activin can be modulated by the capability of follistatin to bind to and inactivate activin. Follistatin interacts with activin A with high anity, and prevents activin binding to its own receptors, thereby blocking activin A-induced signaling (Phillips, 2000) . Recently we and others have shown that FLRG may be involved in the regulation of the biological activity of activin through its binding to activin Tsuchida et al., 2000) .
The TGFb family includes TGFbs, activins and bone morphogenetic proteins (BMP) . Like that of other TGFb family members, activin signaling operates through a heteromeric complex of transmembrane serine/threonine kinase receptors: activin binds to a type II receptor, which recruits, phosphorylates and thereby activates an activin type I receptor propagating signals along the Smad pathway. Activin and TGFb act through Smad2 and Smad3, whereas BMP acts through Smad1 and Smad5. Phosphorylated Smad2 and Smad3 form heteromeric complex with the common mediator Smad4, translocate into the nucleus, and activate the transcription of target genes in a celltype-speci®c manner through interaction with DNA and other nuclear factors (Derynck et al., 1998; Massague and Wotton, 2000; ten Dijke et al., 2000; Wrana, 2000) . Smad6 and Smad7 has been reported to function as negative regulators of TGFb family. Smad7 has been shown to inhibit TGFb and activin signal transduction by blocking type I receptor phosphorylation of Smad2 and Smad3 (Hayashi et al., 1997; Lebrun et al., 1999; Nakao et al., 1997) . Smad6, the other negative regulator of the TGFb family (Imamura et al., 1997) , seems to preferentially inhibit BMP signaling.
In the present study, we analysed the regulation of activin A signaling by FLRG and follistatin, two activin-binding proteins. We have recently shown that TGFb induces transcriptional activation of FLRG in the human hepatoma cell line HepG2 through Smad proteins . We examined the expression of FLRG and follistatin in HepG2 cells following treatment with activin A, a member of TGFb superfamily. We found that follistatin and FLRG were transcriptionally induced by activin A through Smad proteins, and that FLRG, like follistatin, regulated the biological functions of activin A.
Results

Neutralization of activin A-induced transcription activation by FLRG and follistatin proteins
We have shown that FLRG may be involved in the regulation of the biological activity of activin through its binding to activin . In order to analyse the antagonistic eect of the FLRG protein on activin A bioactivity, we ®rst produced a secreted human recombinant FLRG protein, using a baculovirus expression system. We carried out a transcriptional reporter assay using an activin-responsive reporter construct in order to analyse the eect of FLRG protein on activin signaling. HepG2 cells were transiently transfected with the (CAGA) 9 -MLP-Luc reporter vector, which is known to respond to activin A-induced transcription (Dennler et al., 1998) . Twenty-four hours after transfection, the cells were treated with activin A in the presence or absence of FLRG or follistatin proteins. As shown in Figure 1a , b, activin A increased the luciferase activity by more than 30-fold. The addition of FLRG or follistatin alone did not aect the background level of the luciferase activity ( Figure 1a ,b, open bars). The addition of FLRG or follistatin proteins dramatically inhibited the activin A-induced transcription activation in a dose-dependent way (Figure 1a ,b, black bars). As previously reported (Tsuchida et al., 2000) , we found that FLRG protein, like follistatin, can inhibit the activin-induced transcription activation.
Effect of FLRG protein on HepG2 cell growth
Activin A inhibits the growth of primary hepatocytes and HepG2 cells in a dose dependent-way, and follistatin, an activin-binding protein, has been shown to inhibit activin activity in the liver (Phillips and de Kretser, 1998 ). Here we used a¯uometric growth assay to evaluate the eect of exogenous FLRG protein on exponentially growing HepG2 cells. Cells seeded in the presence of activin A did not exhibit any net increase in cell numbers over a 5-day period, as compared to the untreated control culture (Figure 2b ). Thus, as expected, activin A inhibits the proliferation of HepG2 cells, and the eect of activin A on HepG2 proliferation was abolished by adding follistatin protein (data not shown). FLRG protein alone had no eect on cell proliferation (Figure 2a) , while in combination with activin, it neutralized the inhibitory eect of activin A Figure 1 Inhibitory eect of FLRG and follistatin proteins on activin A-induced transcription activation. HepG2 cells were cotransfected with the (CAGA) 9 -MLP-Luc reporter vector (a and b), along with the pRL-CMV internal control vector. Twenty-four hours after transfection, the cells were stimulated by activin A (20 ng/ml), or left unstimulated, in the presence or absence of increasing amounts of FLRG (a) or follistatin (b) proteins, and the luciferase activity was determined 24 h later. This activity (normalized by reference to the renilla luciferase activity) is given as the mean+s.d. of an experiment performed in triplicate, representative of three experiments. Fold-induction calculated by comparing activin-treated cells to untreated control cells is indicated at the top of each black bar on proliferation in a dose-dependent way (Figure 2b ). These results indicate that the exogenous addition of FLRG protein blocks activin A-induced growth inhibition.
Induction of FLRG and follistatin expression by activin A
We have previously reported that TGFb is a potent inducer of FLRG gene expression in human bone marrow stromal cells and the human hepatoma cell line HepG2, as shown at both the protein and mRNA levels Maguer-Satta et al., 2001) . In this study, we investigated whether activin A, a member of the TGFb superfamily, modulated FLRG expression in the HepG2 cell line, which is known to contain functional activin receptors. HepG2 cells were treated for dierent periods of time with activin A, and total cellular RNA was analysed by Northern blot using FLRG or follistatin cDNA probes. As previously shown (Russell et al., 1999; Zhang et al., 1997) , activin A increased follistatin mRNA levels. Treatment of HepG2 cells with activin A induced a high level of time-dependent FLRG mRNA expression. This large increase in FLRG and follistatin transcripts was observed as early as 3 h after the addition of activin A, and it continued to rise over time after the addition of cytokine (Figure 3a) .
To ®nd out if the up-regulating eect of activin A on FLRG and follistatin mRNA was also re¯ected at the protein level, we performed a Western blot with a ®vefold concentrated conditioned medium from cells treated or not with activin A for 48 h. Using antibodies directed against FLRG and follistatin proteins, we observed immunoreactive bands of the expected molecular size (33 and 31 ± 39 kDa), the known M r of glycosylated FLRG and follistatin proteins respectively ( Figure 3b ). These bands were not found in a medium obtained from untreated control cells. These results indicate that activin A is a potent inducer of the expression of the activin ligands, FLRG and follistatin, in the human hepatoma cell line HepG2.
Transcriptional regulation of FLRG and follistatin by activin A
To ®nd out if the increase in FLRG and follistatin expression in the presence of activin A resulted from the transcription activation of the FLRG and follistatin promoters, we used a luciferase-based construct containing these promoters. The pGL3-MLP(73293/ +6) and pGL3-basic(72165/+2) plasmids containing, respectively, the FLRG and follistatin promoters were independently transfected into HepG2 cells and tested for inducibility by activin A. These two constructs led to a threefold activin A-mediated induction (Figure 4 ), which indicated a transcription activation of the FLRG and follistatin promoters in response to the addition of activin A. These results indicate that activin A up- 
Participation of Smad proteins in the activin A-induced expression of FLRG and follistatin
As for other target genes transcriptionally regulated by TGFb or activin (Moustakas and Kardassis, 1998; Nagarajan et al., 1999; Vindevoghel et al., 1998) , we have reported that although Smad3 alone was found to increase FLRG mRNA, the highest transcript level was observed when the Smad2, Smad3 and Smad4 expression vectors were cotransfected . In the present case, we examined the involvement of Smad proteins in follistatin transcriptional activation. For this purpose, we cotransfected the expression vectors for Smad2, Smad3 and Smad4, independently or in combination, into HepG2 cells, along with the follistatin promoter-luciferase construct.
As shown in Figure 5a , the overexpression of Smad3 induced follistatin transcription. Moreover it synergized with Smad4 to stimulate the follistatin promoter, as shown by the fact that the co-expression of Smad3 and Smad4 increased the promoter activity by more than 40-fold.
To analyse the eect of Smad proteins expression on the follistatin mRNA level, we transfected expression vectors for Smad2, Smad3 and Smad4, independently or in combination, into HepG2 cells, and analysed total cellular RNA by Northern blot using follistatin cDNA as a probe. In accordance with the results obtained using the follistatin promoter fused to luciferase (Figure 5a ), a cooperative eect of Smad3 and Smad4 proteins was observed in follistatin mRNA expression ( Figure 5b ).
Next we investigated whether Smad proteins are involved in the activin-mediated activation of FLRG and follistatin promoters. For this purpose, we cotransfected HepG2 cells with FLRG and follistatin promoter-luciferase constructs along with expression vectors encoding the inhibitory Smad7, or C-terminally truncated forms of Smad3 and Smad4, which are known to act as speci®c dominant-negative inhibitors of Smad signaling (Lagna et al., 1996; Zhang et al., 1996) . We found that transfection of Smad7, or Smad3 and Smad4 dominant-negative mutants signi®cantly reduced the activin A-induced transcription of the FLRG and follistatin promoter reporter constructs (Table 1 ). In the presence of Smad7 we observed an inhibition of 77.5 and 45.5% of the activin A-induced FLRG and follistatin transcription, respectively. This Altogether, our results indicate that Smad proteins are involved in FLRG and follistatin regulation by activin A. FLRG and follistatin genes can thus be considered as targets of activin transcriptional activation through the action of Smad proteins.
FLRG protein down-regulates its own activin-induced expression
Finally, we investigated whether the inhibitory eect of FLRG protein on the activin A-induced transcription activation was also obtained with the FLRG promoter reporter construct. For this purpose, HepG2 cells were transiently transfected with the FLRG promoter reporter vector, which is known to respond to activin A-induced transcription (Figure 4 ). Twenty-four h after transfection, the cells were treated with activin A in the presence or absence of FLRG protein. The addition of FLRG alone did not aect the background level of the luciferase activity ( Figure 6 , open bars). The addition of FLRG protein inhibited the activin A-induced transcription activation in a dose-dependent way ( Figure 6 , black bars). This is shown by the fact that the 2.6-fold increase in transcriptional response to activin A which resulted from using the reporter construct containing the FLRG promoter was signi®-cantly reduced by the addition of FLRG protein ( Figure 6 ). These results indicate that the exogenous addition of FLRG protein reduced its own promoter activation when mediated by activin A, and that FLRG protein is involved in a negative feedback loop to modulate activin signaling.
Discussion
TGFb is the prototype of a family of signaling molecules which also includes activins and BMPs. Signaling of TGFb family members such as activin is (Fainsod et al., 1997; Gamer et al., 1999; Iemura et al., 1998) . We and others have already shown that FLRG protein, which is highly homologous to follistatin, associates with activin A, and may participate in the regulation of its biological activity (Hayette et al., 1998; Maguer-Satta et al., 2001; Tsuchida et al., 2000) . FLRG, like follistatin, binds to BMP2, and inhibits BMP-induced transcriptional activation (Tsuchida et al., 2000) .
In the present study, we analysed the regulation of activin A bioactivity by FLRG and follistatin, two activin-binding proteins. Follistatin inhibits activin functions in various cell types (Phillips, 2000) . To assess the ability of FLRG protein to inhibit activin A signaling, we have used a transcriptional assay with a reporter plasmid known to respond to activin A (Dennler et al., 1998) . A dose-dependent inhibitory eect on the transcription activation induced by activin A was obtained by the addition of FLRG or follistatin proteins. It has been reported that in hepatocytes activin-induced cell growth inhibition is antagonized by the exogenous addition of follistatin (Russell et al., 1999; Schwall et al., 1993; Yasuda et al., 1993) . Here, as expected, we found that activin A inhibited the growth of the human hepatoma cell line HepG2. We found that soluble FLRG, like follistatin, blocked activin A-induced growth inhibition in a dose-dependent way. These results indicate that FLRG, a newlycharacterized activin-binding protein, inhibits the eects of activin in HepG2 cells.
The neutralizing eect of follistatin on activin bioactivity results from interference with activin binding to the type II receptor (de Winter et al., 1996) . Further studies will be needed to determine whether FLRG, like follistatin, forms an inactive complex with activin, and thus neutralizes its activity. Activin and follistatin are expressed in many types of tissue, and participate in a number of physiological and developmental processes such as oogenesis, spermatogenesis, hematopoiesis and embryogenesis, and in the pituitary, liver and other tissues (Phillips and de Kretser, 1998) . Similarly, FLRG is expressed in numerous tissues, and during murine embryogenesis (Hayette et al., 1998; Tsuchida et al., 2000) , suggesting that it plays a role in various physiological systems. The high homology between FLRG and follistatin may indicate functional redundancy. However, as we recently demonstrated, FLRG and follistatin expression patterns are dierent in primary hematopoietic subpopulations, which suggests that their expression may be restricted in time and space, and that their activity may not always be redundant.
We have recently shown that TGFb is a potent inducer of FLRG gene expression through Smad proteins . As activin signaling is also mediated by the Smad proteins, we have analysed the regulation of FLRG and follistatin expression, and we observed that activin A increased FLRG and follistatin mRNA levels in HepG2 cells. The stimulatory eect of activin A was found to be time-dependent and associated with an increase in FLRG and follistatin proteins. To investigate the molecular mechanisms underlying the activin-induced expression of FLRG and follistatin, we looked at the promoter activity of the human FLRG and follistatin genes. We found that activin A induced the expression of FLRG and follistatin by a transcriptional mechanism. We have previously demonstrated that Smad proteins, which are critical components of the TGFb-and activin-signaling pathways, are involved in the activation of the FLRG promoter by TGFb ). Here we show that overexpression of the Smad3 and Smad4 proteins increases the follistatin mRNA level. In addition, overexpression of either the inhibitory Smad7 or the dominant-negative Smad3 or Smad4 mutants inhibits the activin-induced activation of the FLRG and follistatin promoters. These results indicate that Smad proteins are involved in the activation of FLRG and follistatin promoters by activin A. To our knowledge, this is the ®rst demonstration of a response by the FLRG and follistatin promoters to activin A.
Several studies have shown that signaling of the TGFb superfamily is regulated at various dierent levels. The transcription of Smad7, a negative regulator of TGFb and activin signal transduction, is regulated by TGFb and activin signaling through Smad proteins (Brodin et al., 2000; Denissova et al., 2000; Nagarajan et al., 1999) . These data indicate that Smad7 is involved in a feedback loop that modulates the eects Figure 6 FLRG protein inhibits activin A-induced transcription activation on its own promoter. HepG2 cells were cotransfected with the FLRG promoter-luciferase construct, along with the pRL-CMV internal control vector. Twenty-four hours after transfection, the cells were stimulated by activin A (20 ng/ml), or left unstimulated, in the presence or absence of increasing amounts of FLRG proteins, and the luciferase activity was determined 24 h later. This activity (normalized by reference to the renilla luciferase activity) is given as the mean+s.d. of an experiment performed in triplicate, representative of three experiments. Fold-induction calculated by comparing activintreated cells to untreated control cells is indicated at the top of each black bar of TGFb and activin A (Piek et al., 1999) . Other signaling pathways, such as interferon-g and tumor necrosis factor-a, which operate, respectively, through JAK1/STAT1 and the nuclear factor-kB/RelA, stimulate the expression of Smad7 to block TGFb signaling (Bitzer et al., 2000; Ulloa et al., 1999) . Thus Smad7 modulates the cellular response to TGFb and activin by using dierent signaling pathways. Smad6, the other negative regulator of the TGFb family (Imamura et al., 1997) , seems to preferentially inhibit BMP signaling. BMP2 and BMP7 increase the Smad6 mRNA level (Takase et al., 1998) , indicating that the inhibitory Smad6 protein may play a role in a feedback loop which regulates BMP signaling. The production of the inhibitory Smad6 and Smad7 proteins by TGFb family members provides an autoinhibitory mechanism in TGFb signaling. An additional level of control of the biological activity of the TGFb family is provided by soluble binding proteins. Small leucine-rich proteoglycans such as decorin and biglycan bind to TGFb and inhibit its activity (Piek et al., 1999) . Noggin, chordin, gremlin, follistatin and FLRG can bind BMP proteins and antagonize their bioactivity (Reddi, 2001; Smith, 1999; Tsuchida et al., 2000) . Our results and previous reports Phillips and de Kretser, 1998; Tsuchida et al., 2000) indicate that follistatin and FLRG reduce the biological eects of activin A, and may play a role in regulating the bioavailability of activin.
In conclusion, activin A induces FLRG and follistatin transcription through the action of Smad proteins. This observation, in conjunction with the inhibitory eect of FLRG and follistatin on activin function indicates that these two activin-binding proteins participate in a negative feedback loop that regulates activin signaling. Moreover, we found that FLRG protein regulates its own activin-induced expression. The induction of FLRG and follistatin by activin A may protect cells from excessive exposure to activin. Similarly, it has been shown that BMP proteins induce the expression of gremlin and noggin, two secreted proteins which inhibit BMP activity (Gazzerro et al., 1998; Pereira et al., 2000) . In all, these observations suggest that soluble proteins like inhibitory Smad proteins play a central role in the negative autoregulation of TGFb family signaling.
Materials and methods
Cell cultures
The human hepatoma cell line HepG2 was obtained by American-Type Culture Collection (ATCC), and cultured in Dulbecco's modi®ed Eagle's medium containing 10% fetal calf serum (FCS), 0.03% L-glutamine, 100 mg/ml penicillin and 100 mg/ml streptomycin sulfate.
FLRG production
Human recombinant FLRG protein was produced in Sf9 cells using a baculovirus expression system according to the manufacturer's instructions (Pharmingen). FLRG cDNA encoding the human FLRG protein, residues 27 to 263, was subcloned into the pAcGP67 baculovirus transfer vector fused to the sequence coding for the gp67 signal peptide, under the control of the strong baculovirus polyhedrin promoter. The concentration of the secreted recombinant FLRG protein, which was produced in a serum-free medium, was estimated on a polyacrylamide gel by silver staining using de®ned amounts of recombinant 6His-FLRG protein produced in a bacterial system.
Plasmid constructs
To study the transcriptional regulation of human follistatin gene expression, we subcloned the follistatin promoter between position 72165 and +2 relative to the major transcription start site (Shimasaki et al., 1988) into the pGL3-basic luciferase reporter gene vector (lacking promoter and enhancer sequences; Promega), giving the pGL3-basic(72165/+2). For this purpose, human genomic DNA extracted from normal peripheral blood lymphocytes was used as a template for PCR reaction, with primers selected from genomic sequences which contain the follistatin gene, and which are available in the public domain (accession No. AC008901). To study the transcriptional regulation of human FLRG gene expression, we used the pGL3-MLP(73293/+6) plasmid containing the FLRG promoter elements between nucleotides 72306 and +6, which promote the expression of the luciferase reporter gene. All the constructs were sequence-checked.
Mammalian expression vectors encoding¯ag-tagged human Smad2, Smad3, Smad4 and Smad7 were kindly provided by P ten Dijke (Ludwig Institute for Cancer Research, Uppsala, Sweden). Mammalian expression vectors encoding the dominant-negative human Smad3 (DN-Smad3) and Smad4 (DN-Smad4) proteins were kindly provided by R Derynck (University of California, CA, USA). The pGL3(CAGA) 9 -MLP-Luc reporter vector with nine copies of the CAGA sequence is known to respond to TGFb-and activin A-induced transcription (Dennler et al., 1998) , was kindly provided by JM Gauthier (Glaxo Wellcome laboratory, Les Ullis, France).
Transient tranfections and reporter assays
For transient transfections, HepG2 cells were seeded in 12-well plates (1.4610 5 cells per well) and transfected 48 h later by Exgen 500 (Euromedex, Souelweyersheim, France) with the indicated reporter constructs (800 ng) and the pRL-CMV internal control vector (25 ng) under the control of the cytomegalovirus promoter (Promega). When Smad expression vectors were cotransfected, the same amount of Smad expression vector was transfected in each case (150 ng for Smad2, Smad3 and Smad4, and 350 ng for DN-Smad3, DNSmad4 and Smad7), and total DNA was kept constant (1.25 mg) by the addition of an empty vector. Twenty ng/ml of human recombinant activin A (R&D) was added 24 h after transfection, and the luciferase activity was quanti®ed in the cell lysates after a further 24 h using the Dual Luciferase Assay (Promega). All the experiments were performed in triplicate, and the luciferase activity was normalized with regard to the renilla luciferase activity expressed by the pRL-CMV vector (Promega).
For Northern blot analysis, HepG2 cells were seeded in six-well plates (4610 5 cells per well) and transfected 24 h later by Exgen 500 with expression vectors for Smad2, Smad3 and Smad4, either independently or in combina-tion. The same amount of Smad expression vector (650 ng) was transfected in each case, and total DNA was kept constant (2 mg) by the addition of an empty vector. Total RNA from the transfected cells was extracted 48 h later.
Alamar blue proliferation assay
To quantitatively measure the proliferation of HepG2 cells, we used the Alamar Blue assay (BioSource International), which incorporates a¯uometric/colorimetric growth indicator based on the detection of metabolic activity by monitoring the reducing environment of the proliferating cells. HepG2 cells were seeded in 96-well microtiter plates at 3000 cells per well in 200 ml of DMEM containing 10% FCS, then incubated for 5 days with 10 ng/ml of activin A (R&D), follistatin (R&D), and FLRG, either independently or in combination. After various incubation times at 378C, Alamar Blue was added, and the reduction was monitored by a¯uorometer 5 h after the addition of the Alamar Blue to the culture. Fluorescence measurements were made by exciting at 530 ± 560 nm and measuring emission at 590 nm. After background subtraction, data are expressed in uorescence emission-intensity units as a function of incubation time.
Northern blot analysis
Total cellular RNA was puri®ed by the acid guanidium thiocyanate-phenol-chloroform method using the TRIzol reagent as per the manufacturer's instructions (Gibco ± BRL). For Northern blot analysis, 10 mg of total RNA were size-fractionated in formaldehyde-1.2% agarose gels and transferred onto nylon ®lters. The probes were labeled with a-32 P-dCTP using the Rediprime labeling kit (Amersham Pharmacia Biotech) and hybridized according to standard procedures. The gel was stained with ethidium bromide to visualize ribosomal RNA as a way of con®rming equal RNA loading.
Western blot analysis
A ®vefold concentrated conditioned medium obtained from a low-concentration serum culture (1% FCS) derived from HepG2 cells, either treated or not treated with activin A (20 ng/ml), was subjected to electrophoresis on a 12% SDSpolyacrylamide gel in denaturing and reducing conditions. The separated proteins were transferred onto a membrane (Millipore) by electroblotting. After blocking with a 5% nonfat milk solution, the ®lters were incubated with the rabbit polyclonal antisera raised against FLRG (Hayette et al., 1998) , or with an anti-follistatin monoclonal antibody (R&D). Bound primary antibodies were detected with horseradish peroxydase-labeled anti-rabbit or anti-mouse secondary antibodies. Finally, the membranes were washed and developed with chemiluminescence reagents (ECL system, Amersham Pharmacia Biotech).
